Improvement seen in treatment satisfaction and several secondary end points for depot buprenorphine versus sublingual buprenorphine
Differences between the two trajectories persist in opioid fills, misuse beyond 12 months
8-mg dose of naloxone hydrochloride nasal spray now approved with 2-mg and 4-mg doses